Literature DB >> 3743620

Biliary excretion and pharmacokinetics of ceftriaxone after cholecystectomy.

W L Hayton, R Schandlik, K Stoeckel.   

Abstract

Three groups of patients with biliary tract disease treated by cholecystectomy were given ceftriaxone. In Group 1 single doses of 150 mg and 1500 mg were given on Days 1 and 5 after cholecystectomy. In Group 2 2 g was given daily for 6 days and the cholecystectomy was on Day 2. Patients in Group 3 received 2 g every 12 h for 3 to 5 doses before cholecystectomy. Plasma samples, urine and T-drain bile were collected at various times from Groups 1 and 2 patients. Gallbladder bile and plasma were collected from Group 3 patients at the time of cholecystectomy. The mean (+/- SEM) T-drain bile-to-plasma concentration ratio of ceftriaxone in Groups 1 and 2 was 6.7 +/- 0.92. The mean (+/- SEM) gallbladder bile-to-plasma concentration ratio was 33 +/- 4.2. No clinically significant differences were detected between the kinetics of ceftriaxone in the cholecystectomy patients compared to normal volunteers. The usual dosage of ceftriaxone appeared adequate for prophylaxis or treatment of biliary tract infection by susceptible organisms.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3743620     DOI: 10.1007/bf00607958

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Ceftriaxone: renal and biliary excretion and effect on the colon microflora.

Authors:  A Arvidsson; G Alván; B Angelin; O Borgå; C E Nord
Journal:  J Antimicrob Chemother       Date:  1982-09       Impact factor: 5.790

2.  Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose.

Authors:  P J McNamara; K Stoeckel; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

3.  Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations.

Authors:  P J McNamara; M Gibaldi; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 4.  Excretory function of the liver.

Authors:  J Reichen; G Paumgartner
Journal:  Int Rev Physiol       Date:  1980

Review 5.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

6.  Biliary excretion and pharmacokinetics of cefoperazone in humans.

Authors:  B Kemmerich; H Lode; K Borner; D Belmega; T Jendroschek; P Koeppe; G Goertz
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

7.  Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model.

Authors:  K Stoeckel; J R Koup
Journal:  Am J Med       Date:  1984-10-19       Impact factor: 4.965

8.  Excretion of cefamandole, cefazolin, and cephalothin into T-tube bile.

Authors:  K R Ratzan; H B Baker; I Lauredo
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

9.  Age-associated changes in ceftriaxone pharmacokinetics.

Authors:  W L Hayton; K Stoeckel
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

10.  Pharmacokinetic and microbial susceptibility studies of ceftriaxone.

Authors:  J D Baumgartner; M P Glauser
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

View more
  18 in total

1.  Penetration of ceftriaxone and cefoperazone into bile and gallbladder tissue in patients with acute cholecystitis.

Authors:  R Orda; S A Berger; Y Levy; A Shnaker; A Gorea
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

2.  Clearance of ceftriaxone in critical care patients with acute renal failure.

Authors:  G Heinemeyer; J Link; W Weber; V Meschede; I Roots
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

3.  The complex dynamics of antimicrobial activity in the human gastrointestinal tract.

Authors:  Louis B Rice
Journal:  Trans Am Clin Climatol Assoc       Date:  2013

Review 4.  Antibiotics and gastrointestinal colonization by vancomycin-resistant enterococci.

Authors:  L B Rice
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

5.  Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs.

Authors:  A Cavalier; D Levêque; J D Peter; J Salmon; H Elkhaïli; Y Salmon; P Nobelis; J Geisert; H Monteil; F Jehl
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

6.  Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies.

Authors:  Tracey Roberts; John F Kokai-Kun; Olivia Coughlin; Barbara Valero Lopez; Heidi Whalen; J Andrew Bristol; Steven Hubert; James Longstreth; Kenneth Lasseter; Joseph Sliman
Journal:  Clin Drug Investig       Date:  2016-09       Impact factor: 2.859

7.  Biliary excretion of ceftriaxone.

Authors:  W Hayton; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 8.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

9.  Apparent biliary pseudolithiasis during ceftriaxone therapy.

Authors:  K L Heim-Duthoy; E M Caperton; R Pollock; G R Matzke; D Enthoven; P K Peterson
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

10.  Pharmacokinetics of ceftriaxone in liver-transplant recipients.

Authors:  A Toth; H Y Abdallah; R Venkataramanan; L Teperman; G Halsf; M Rabinovitch; G J Burckart; T E Starzl
Journal:  J Clin Pharmacol       Date:  1991-08       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.